The break up comes due to Novo Nordisk’s claims that Hims & Hers has “failed to adhere to the law” by continuing to sell compounded versions of Wegovy.
This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth company Hims & Hers Health, Inc. (NYSE: HIMS), citing concerns over Hims & Hers’ “knock-off” weight loss drugs. Now, Hims & Hers’ shares are plummeting as investors react to the news.
